Home
|
About IAC
|
Contact
|
A-Z Index
|
Donate
|
Shop
|
SUBSCRIBE
Immunization Action Coalition
IAC Home
|
Vaccine Timeline

Vaccine Timeline

Historic Dates and Events Related to Vaccines and Immunization

It was not too many years ago when we celebrated the 200th anniversary of Edward Jenner's first smallpox vaccination in 1796. The development of vaccines continued at a fairly slow rate until the last several decades when new scientific discoveries and technologies led to rapid advances in virology, molecular biology, and vaccinology. The chart which follows displays many of the vaccine- and immunization-related events that have occurred since Jenner's critical discovery. This list is by no means exhaustive. If you know of an event that you would like us to add, contact us at admin@immunize.org
 
Date Event and related notes
May 17, 2013 Booster dose of yellow fever vaccine not needed, according to WHO. A single dose of vaccine is effective in providing long-term protection from yellow fever.
February 22, 2013 ACIP recommended a dose of Tdap vaccine during each pregnancy.
February 8, 2013 UNICEF and WHO condemned attacks on polio vaccination workers in Nigeria.
January 25, 2013 FDA approved use of Prevnar 13 vaccine in older children and teens (6-17 years).
December 18, 2012 Institute for Safe Medication Practices (ISMP) launched new Vaccine Error Reporting Program.
December 12, 2012 FDA approved quadrivalent formulation of Fluarix (inactivated influenza vaccine; GlaxoSmithKline).
November 20, 2012 FDA approved first seasonal influenza vaccine manufactured using cell culture technology (Flucelvax, Novartis).
October 24, 2012 ACIP voted to recommend use of HibMenCY (Menhibrix, GlaxoSmithKline), a new combination (meningococcal and Hib) vaccine, in infants at increased risk for meningococcal disease.
October 24, 2012 ACIP voted to recommend that pregnant women receive a dose of Tdap during each pregnancy irrespective of the patient's prior history of receiving Tdap.
June 24, 2012 FDA approved HibMenCY (Menhibrix, GlaxoSmithKline), a new combination (meningococcal and Hib) vaccine for infants.
June 7, 2012 FDA expanded licensure of PCV13 to include adults ages 50 years and older.
June 5, 2012 U.S. Department of Health and Human Services (HHS) Office of the Inspector General (OIG) released a report titled "Vaccines for Children (VFC) Program: Vulnerabilities in Vaccine Management."
April 1, 2012 United Nations Foundation launched Shot@Life campaign.
December 30, 2011 FDA expanded use of Prevnar 13 (PCV13, Pfizer) vaccine to include people ages 50 and older.
October 25, 2011 ACIP recommended all 11 to 12 year-old males get vaccinated against HPV.
October 21, 2011 Addition of history of intussusception as a contraindication for rotavirus vaccination.
August 25, 2011 National survey indicated HPV vaccine rates trail other teen vaccines.
August 25, 2011 Institute of Medicine issued the report titled "Review of Adverse Effects of Vaccines." Overall, the committee concludes that few health problems are caused by or clearly associated with vaccines.
July 8, 2011 FDA approved Boostrix (Tdap, GlaxoSmithKline) to prevent tetanus, diphtheria, and pertussis in older people.
May 19, 2011 CDC hailed vaccinations as one of 10 public health achievements of first decade of 21st century in Morbidity and Mortality Weekly Report (MMWR).
April 22, 2011 FDA approved the first vaccine (Menactra, meningococcal conjugate vaccine, sanofi pasteur) to prevent meningococcal disease in infants and toddlers.
February 15, 2011 HHS releases U.S. National Vaccine Plan, covers activities, goals, and priorities for 2010-2015.
December 22, 2010 FDA approved Gardasil HPV vaccine to include the indication for the prevention of anal cancer.
August 11, 2010 WHO declared end to 2009 H1N1 influenza pandemic.
July 10, 2010 First smallpox vaccine for certain immune-compromised populations delivered under Project BioShield.
March 19, 2010 ACIP recommended use of a reduced (4-dose) vaccine schedule for PEP to prevent human rabies.
February 24, 2010 FDA approved licensure of Pneumococcal 13-valent conjugate vaccine (PCV13), which offers broader protections against Steptococcus pneumoniae infections.
February 19, 2010 FDA approved licensure of Menveo (Novartis), meningococcal conjugate vaccine for people ages 11 through 55 years.
January 29, 2010 WHO hailed new Gates Foundation support ($10 billion) as the "Decade of Vaccines."
February 24, 2010 ACIP recommended universal Influenza vaccination for those 6 months of age and older.
February 24, 2010 FDA approved pneumococcal 13-valent conjugate vaccine (Prevnar 13), which offers broader protection against Streptococcus pneumoniae.
December 23, 2009 FDA approved high-dose inactivated influenza vaccine (Fluzone High-Dose) for people ages 65 years and older.
November 16, 2009 CDC issued Health Advisory 2009 H1N1 Pandemic Update: Pneumococcal vaccination recommended to help prevent secondary infections.
October 21, 2009 Merck issued announcement that the company will not resume production of monovalent measles, mumps, and rubella vaccines.
October 16, 2009 FDA approved new vaccine (Cervarix, GlaxoSmithKline) for the prevention of cervical cancer.
October 16, 2009 FDA approved new indication for gardasil to prevent genital warts in men and boys.
September 15, 2009 FDA approved four vaccines against the 2009 H1N1 influenza virus.
July 1, 2009 WHO and ACIP issued recommendations on the use of H1N1 influenza vaccines.
June 23, 2009 HHS announced advanced development contract for new way to make flu vaccine.
June 11, 2009 Dr Margaret Chan, Director-General WHO, declared world now at the start of 2009 influenza pandemic.
May 22, 2009 HHS directed $1 billion toward development of vaccine for novel influenza A (H1N1).
March 16, 2009 ACIP voted to recommend hepatitis A vaccination for close contacts of international adoptees from countries with high and intermediate endemicity.
February 12, 2009 Vaccine Court ruled that MMR vaccine, when administered with thimerosal-containing vaccines, does not cause autism.
January 15, 2009 HHS awarded a $487 million contract to Novartis Vaccines and Diagnostics, Inc to build a facility to manufacture cell-based influenza vaccine.
December 11, 2008 FDA approved changes in the schedule for administering anthrax vaccine (BioThrax, manufactured by Emergent BioSolutions) and in the route of administration.
December 4, 2008 FDA approved expanded indication for use of Boostrix Tdap vaccine in people ages 10-64 years.
October 27, 2008 National Quality Forum included the hepatitis B birth dose among its consensus standards for improving health care for mothers and newborns.
June 24, 2008 FDA approved new DTaP-IPV vaccine (Kinrix) for use in children ages 4-6 years.
June 5, 2008 FDA approved the use of sanofi pasteur's Tenivac tetanus and diphtheria toxoids adsorbed for adults age 60 years and older. In the original licensure, the age indication was for persons ages 7-59 years.
April 3, 2008 FDA approved new rotavirus vaccine (Rotarix) for use in U.S. Rotarix is a liquid and given in a two-dose series to infants from 6 to 24 weeks of age.
April 2, 2008 CDC issued Health Advisory in response to widespread measles outbreaks in U.S.
March 14, 2008 CDC updated its recommendations for administering combination MMRV vaccine.
February 29, 2008 CDC announced it had begun distribution of a new-generation smallpox vaccine, ACAM2000 (Acambis, Inc., Cambridge, Massachusetts), to civilian laboratory personnel, the military, and state public health preparedness programs.
February 27, 2008 ACIP voted to expand influenza recommendation to include vaccination for children ages 6 months-18 years.
December 7, 2007 CDC published updated recommendation for meningococcal vaccination of at-risk children age 2-10 years in MMWR.
October 26, 2007 ACIP voted to recommend the use of FluMist, the live attenuated influenza vaccine (LAIV; nasal-spray formulation) to include children age 2-5 years.
October 19, 2007 CDC published updated recommendations for prevention of hepatitis A virus infection after exposure and before international travel in MMWR.
October 18, 2007 FDA approved use of Menactra, a bacterial meningitis vaccine, in children age 2-10 years.
September 28, 2007 FDA approved Afluria, a new inactivated influenza vaccine for use in people age 18 years and older.
September 19, 2007 FDA approved use of FluMist nasal-spray influenza vaccine in children age 2-5 years.
August 10, 2007 CDC notified MMWR readers of revised recommendations to vaccinate all persons ages 11-18 with MCV4 at earliest opportunity.
July 20, 2007 MMWR notified readers that revised International Health Regulations have gone into effect for the United States.
July 17, 2007 HHS announced a plan to provide $175 million to assist states in pandemic influenza preparedness efforts.
June 27-28, 2007 ACIP voted to recommend routine use of meningococcal conjugate vaccine in adolescents ages 11-18 years.
June 15, 2007 HHS awarded $132.5 million to sanofi pasteur and MedImmune over five years to retrofit existing domestic vaccine manufacturing facilities on a cost-sharing basis and to provide warm-base operations for manufacturing pandemic influenza vaccines.
March 28, 2007 FDA approved an accelerated dosing schedule for Twinrix (hepatitis A and B vaccine). The schedule consists of three doses given within three weeks followed by a booster dose at 12 months (0, 7, 21–30 days, 12 months).
April 17, 2007 FDA approves first U.S. vaccine for humans against the avian influenza virus H5N1.
January 7, 2007 FDA licensed the refrigerator formulation of FluMist.
June 29, 2006 ACIP recommends second dose of varicella vaccine for children.
June 8, 2006 FDA licensed the first vaccine developed to prevent cervical cancer (Gardasil by Merck & Co., Inc.), precancerous genital lesions, and genital warts due to human papillomavirus (HPV) types 6, 11, 16, and 18.
May 25, 2006 FDA licensed a new vaccine to reduce the risk of shingles (herpes zoster) in the elderly. The vaccine (Zostavax by Merck & Co., Inc.) is approved for use in people aged 60 years of age and older.
Feb 24, 2006 VariZIG, a new immune globulin product for postexposure prophylaxis of varicella, is available under an Investigational New Drug Application Expanded Access Protocol.
Feb 3, 2006 Rotavirus vaccine, live, oral, pentavalent (RotaTeq by Merck) was licensed for use in infants ages 6 to 32 weeks.
Dec 19, 2005 A final order on the anthrax vaccine was issued by FDA, stating that the licensed anthrax vaccine is safe and effective for the prevention of anthrax disease, regardless of the route of exposure.
Oct 18, 2005 FDA approved lowering the age limit to 12 mos for the remaining U.S.-licensed hepatitis A vaccine in the U.S. (Havrix by GlaxoSmithKline).
Oct 7, 2005 A new Federal Medicare rule became effective that required all long-term care facilities to offer annual vaccination for influenza and one-time vaccination for pneumococcal disease to all residents as a condition of participation in Medicare.
Sept 6, 2005 A vaccine that combined the measles, mumps, rubella, and varicella antigens (Proquad by Merck) was licensed. The vaccine was indicated for use in children 12 months to 12 years.
Aug 31, 2005 An inactivated, injectable influenza vaccine (Fluarix by GlaxoSmithKline) was licensed. The vaccine was indicated for adults 18 years of age and older.
Aug 11, 2005 FDA approved lowering the age limit to 12 mos for one of the two licensed hepatitis A vaccine (Vaqta by Merck).
June 10, 2005 FDA licensed a 2nd Tdap vaccine (Adacel by sanofi pasteur) for use in persons ages 11-64 years.
May 3, 2005 An acellular pertussis vaccine combined with the adult formulation of tetanus and diphtheria (Tdap: Boostrix by GSK) was licensed for use as an active booster in persons 10-18 years of age. This product became the first licensed acellular pertussis-containing vaccine with an indication for adolescents.
April 3, 2005 DHHS awarded a contract for $97 million to sanofi pasteur to develop cell culture-based influenza vaccines for the U.S.
March 21, 2005 CDC announced that rubella was no longer endemic in the U.S.
Jan 14, 2005 The first meningococcal polysaccharide (Serogroups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (Menactra by sanofi pasteur) was licensed. This marked the first meningococcal vaccine that was immunogenic and indicated for children younger than 2 years of age.
Aug - Oct, 2004 A significant shortage of influenza vaccine occurred in the U.S. (History: On August 25, 2004, as a result of routine testing required by FDA, Chiron Corporation, located in the U.K. and one of two suppliers of inactivated influenza vaccine for the U.S., identified bacterial contamination in a limited number of lots (approx 4.5 million doses) of its influenza vaccine. Chiron was expected to produce between 46 and 48 million doses of vaccine for the U.S. as part of a total vaccine supply of about 100 million doses. On Oct 4, 2004, authorities in the U.K. suspended the company's license for 3 months. On Oct 16, 2004, FDA announced that none of the influenza vaccine manufactured by Chiron for the U.S. market was safe for use. U.S. authorities recommended allocation of vaccine to those at highest risk of complications from influenza.)
May 4, 2004 The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institute of Health (NIH), awarded a new license agreement for RotaShield, an oral rotavirus vaccine, created by NIAID scientists in the 1980s. The licensed was awarded to BIOVIRx, Inc., of Minneapolis, MN, which planned global commercialization of RotaShield.
May 2004 Contracts were awarded to Aventis Pasteur and to Chiron to develop vaccine against the H5N1 avian influenza virus.
2004 The 8th and final report of the Immunization Safety Review Committee was issued by the Institute of Medicine. The report concluded that the body of epidemiological evidence favors rejection of a causal relationship between the MMR vaccine (and thimerosal-containing vaccines) and autism.
March 24, 2004 Tetanus and diphtheria toxoids adsorbed for adult use (Decavac by Aventis Pasteur), preservative-free, was licensed.
Oct. 15, 2003 ACIP voted to recommend that children 6 to 23 months of age be vaccinated annually against influenza, with implementation scheduled for the fall of 2004.
2003 $81 million was awarded by NIAID through four new contracts to support development of candidate HIV vaccines. The awards were part of NIAID's HIV Vaccine Design and Development Teams program, a public-private partnership that seeks to accelerate HIV vaccine development. The contract recipients were AlphaVAx Human Vaccines, Inc. (Durham, NC), Epimmune, Inc. (San Diego, CA), Novavax, Inc. (Columbia , MD), and Progenics Pharmaceuticals (Tarrytown, NY).
2003 Project Bioshield Act of 2003 was enacted. It authorized more than $5 billion over 10 years to pay for development of vaccines, drugs, and other biomedical countermeasures for biological, chemical, nuclear, and radiological weapons. The Act also empowered the Secretary of Health and Human Services to authorize the use of drugs and vaccines not licensed by the FDA in the event of an act of bioterrorism or other public health emergencies.
June 17, 2003 The first nasally administered influenza vaccine (FluMist by MedImmune) was licensed. This live influenza A and B virus vaccine was indicated for healthy, non-pregnant persons ages 5-49 years.
Dec 13, 2002 A vaccine that combined the diphtheria, tetanus, acellular pertussis, inactivated polio, and hepatitis B antigens (Pediarix by GlaxoSmithKline) was licensed.
June 21, 2002 The European Region of the world was certified as polio-free.
May 14, 2002 Diphtheria and tetanus toxoids and acellular pertussis vaccine (Daptacel by Aventis Pasteur) was licensed.
Feb 25, 2002 GlaxoSmithKline announced that the company would no longer manufacture or distribute its Lyme disease vaccine, LYMErix, because of insufficient sales of the vaccine.
Dec 13, 2002 President Bush announced a major smallpox vaccination program to protect the nation against the threat of potential biological warfare. The first phase of the program was targeted to 450,000 public health and healthcare personnel, however, the program stalled, with fewer than 40,000 health care workers and emergency responders vaccinated.
2001 The Bill and Melinda Gates Foundation earmarked $70 million to develop and produce meningitis vaccines tailored for children and adults living in Africa.
2001 Following the events of September 11, 2001, IOM again called for creation of a national vaccine authority ""to advance the development, production, and procurement of new and improved vaccines of limited commercial potential but of global public health need.""
May 11, 2001 A combined hepatitis A inactivated and hepatitis B (recombinant) vaccine (Twinrix by SmithKline Beecham) was licensed.
Feb 17, 2000 A 7-valent pneumococcal conjugate vaccine (Prevnar by Wyeth Pharmaceuticals) was licensed for use in infants at 2, 4, 6 and 12-15 months of age to prevent invasive pneumococcal disease
2000 Measles was declared no longer endemic in the U.S. following eradication campaigns that began in 1967.
2000 The Western Pacific Region of the world was certified as polio-free.
Dec 9, 1999 Diphtheria and tetanus toxoids and acellular pertussis vaccine (Tripedia by Connaught) was licensed.
Oct 22, 1999 ACIP voted to withdraw their recommendation for rotavirus vaccine after investigating reports of intussusception (a type of bowel obstruction that occurs when one part of the intestine folds into an immediately adjoining part) in infants within the first two weeks of receipt of the vaccine. Intussusception was found to occur at a rate of approximately 1 case for every 5,000 children vaccinated.
Oct 16, 1999 Wyeth Lederle Vaccines voluntarily withdrew Rotashield from the market.
Fall 1999 A meningococcal group C conjugate vaccine was introduced into the routine schedule in the U.K. for infants, adolescents (15-17 yrs), and college entrants. A second phase was planned to begin in January 2000, subject to availability of vaccine.
Sept 1999 FDA approved a 2-dose schedule of hepatitis B vaccination for adolescents 11-15 years of age using Recombivax HB (Merck) with the 10 µg (adult) dose at 0 and 4-6 months later.
June 17, 1999 ACIP recommended exclusive use of inactivated poliovirus vaccine (IPV) for infants and children
1999 The Dale and Betty Bumpers Vaccine Research Center (VRC) was established at the National Institutes of Health to facilitate research in vaccine development. The primary focus of VRC research was to be the development of vaccines for AIDS.
1998 ACIP recommended DTaP vaccines for all five doses in the vaccination schedule, because local reactions, fever, and other systemic events were found to occur substantially less often after DTaP administration than after administration of whole cell DTP.
Aug 26, 1998 The Children's Vaccine Program was established at WHO's Program for Appropriate Technology in Health (PATH) with a $125 million gift from the Bill and Melinda Gates Foundation. The program's goal was to provide vaccines to children in the developing world and to accelerate research and development of new vaccines. The first vaccines purchased were Hib, hepatitis B, rotavirus, and pneumococcal, which were not commonly used in the developing world.
Dec 21, 1998 Lyme Disease Vaccine (Recombinant OspA), (LYMErix by SmithKline Beecham) was licensed for use in persons ages 15 to 70 years. ACIP recommended that decisions on the use of the vaccine be made on the basis of assessment of individual risk, which included the extent of both person-tick contact and geographic risk. Just 3+ years later, on February 25, 2002, GlaxoSmithKline announced that the company would no longer manufacture or distribute LYMErix because of insufficient sales of the vaccine.
Aug 31, 1998 Rotavirus vaccine, live, oral, tetravalent (RotaShield by Wyeth) was licensed for use in infants at 2, 4, and 6 months of age.
July 29, 1998 Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (Certiva by North American Vaccine) was licensed for primary and booster immunization of infants and children (except as a 5th dose in children who have previously received 4 doses of DTaP).
1998 The first vaccine for the prevention of HIV/AIDS (Aidsvax) entered Phase III trial, the first large-scale human trial of an HIV vaccine. The trial involved more than 5,400 volunteers from the U.S., Canada, and the Netherlands, the majority of whom were men who have sex with men. Preliminary results from the trial AIDS VAX (VaxGen) vaccine were reported in early 2003. The HIV vaccine appeared to show a protective effect among non-Caucasian populations, especially African Americans, although sample sizes were small. However, for the majority of the participants, who were Caucasians, the effect of the vaccine was minimal.
Nov 21, 1997 The FDA Modernization Act (FDAMA) was signed into law, amending the Food, Drug and Cosmetic Act and the Public Health Service Act to modernize the regulation of food, medical products, and cosmetics. FDAMA initiatives included measures to modernize the regulation of biological products. Specifically, changes included eliminating the need for establishment license applications, streamlining the approval processes for manufacturing changes, and reducing the need for environmental assessment as part of a product application.
1997 ACIP recommended booster doses of pneumococcal polysaccharide vaccine after 5 years for persons at highest risk of disease.
Oct 20, 1997 Rabies vaccine (RabAvert by Chiron Behring) was licensed.
Jan 29, 1997 Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (Infanrix by SmithKline Beecham) was licensed for the first four doses of the series.
Jan 1997 ACIP recommended adoption of a sequential series of two doses of IPV followed by two doses of OPV for all infants and children to decrease the rare occurrences of Vaccine Associated Paralytic Polio (VAPP) that were noted following the administration of live oral poliovirus vaccine.
Dec 30, 1996 Diphtheria and tetanus toxoids and acellular pertussis vaccine (Acel-Imune by Lederle) was licensed for use as the first through fifth doses in the series.
Sept 27, 1996 Combination DTaP and Hib vaccine (TriHIBit by Aventis Pasteur) was licensed for the fourth dose in the DTaP and Hib series.
July 31, 1996 Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (Tripedia by Aventis Pasteur) was licensed for primary and booster immunization of infants.
1996 The Interational AIDS Vaccine Initiative (IAVI) was launched, calling for the speedy development of a human immunodeficiency virus (HIV) vaccine for use worldwide. The Initiative created the Scientific Blueprint for AIDS Vaccine Development. Since 1996, IAVI invested nearly $20 million in the research and development of HIV vaccines by companies and research institutes worldwide. IAVI received major financial support from the Bill and Melinda Gates Foundation; the World Bank; the Rockefeller, Sloan and Starr foundations; Becton, Dickinson & Co.; and eight national governments, among other donors. IAVI is a Collaborating Centre of the Joint United Nations Programme on HIV/AIDS (UNAIDS).
Oct 2, 1996 A combined Haemophilus influenzae type b conjugate and hepatitis B vaccine (Comvax by Merck) was licensed.
Mar 29, 1996 A second inactivated hepatitis A vaccine (Vaqta by Merck) was licensed.
Feb 22, 1995 The first inactivated hepatitis A vaccine (Havrix by SmithKline Beecham) was licensed.
Mar 17, 1995 Varicella virus vaccine, live (Varivax by Merck) was licensed for the active immunization of persons 12 months of age and older.
1995 The ACIP, American Academy of Pediatrics, and the American Association of Family Physicians issued the first "harmonized" childhood immunization schedule, combining recommendations of all three national groups.
Nov 28, 1994 Typhoid Vi polysaccharide inactivated injectable polysaccharide vaccine (Typhim Vi by Aventis Pasteur) was licensed.
1994 The Global Programme for Vaccines and Immunization was created, merging two WHO programs -- the Expanded Programme for Immunization and the former Programme for Vaccine Development, and adding a new unit for Vaccine Supply and Quality.
1994 The entire Western Hemisphere was certified as "polio-free" by the International Commission for the Certification of Polio Eradication, WHO.
1993 The Institute of Medicine published "The Children's Vaccine Initiative: Achieving the Vision." Later, following the events of September 11, 2001, the Institute of Medicine again called for creation of a national vaccine authority ""to advance the development, production, and procurement of new and improved vaccines of limited commercial potential but of global public health need.""
1993 The National Immunization Program (NIP) was created as a separate program reporting directly to the Office of the Director at CDC. NIP was established to provide federal leadership and services to all local and state public health departments involved in immunization activities (e.g., disease surveillance for vaccine-preventable diseases, development of vaccine information management systems).
May 1, 1993 The costs of influenza vaccine and its administration became a covered benefit under Medicare Part B.
March 1993 Conjugated Haemophilus influenzae type b vaccines (ActHIB by Connaught/Mérieux and OmniHib by SmithKline Beecham) were licensed.
March 1993 A combined Haemophilus influenzae type b vaccine and whole cell DTP vaccine (Tetramune by Lederle/Praxis) was licensed.
1993 The development of immunization registries was promoted at the national level. A national health goal for 2010 was subsequently established to increase the participation in population-based immunization registries to 95%.
1993 The Vaccines for Children Program was established after passage of the Omnibus Budget Reconciliation Act of 1993. Federally-purchased vaccines under this program were made available to children from birth through 18 years of age who met one of the following requirements: Medicaid-enrolled, without health insurance, and American Indian or Alaskan native. Also, children with health insurance that did not cover the costs of immunization were eligible to receive vaccines at a federally-qualified health center or a rural health clinic. All ACIP recommended vaccines received funding, which included new vaccines, new vaccine combinations, and revised recommendations for vaccine use.
Dec 10, 1992 Japanese encephalitis (JE) virus vaccine inactivated (JE-Vax by Research Foundation for Microbial Diseases of Osaka University [BIKEN]) was licensed. JE is the leading cause of viral encephalitis in Asia. WHO acts as a facilitator for the development of new JE vaccines that are safer, require fewer doses, and are more suitable for public health use, in particular, in disease-endemic developing countries.
Sept 20, 1992 Diphtheria and tetanus toxoids and acellular pertussis vaccine (Tripedia by Connaught) was licensed for use as the fourth and fifth doses in the series.
Dec 17, 1991 Diphtheria and tetanus toxoids and acellular pertussis vaccine (Acel-Imune by Lederle) was licensed for use as the fourth and fifth doses in the series.
Nov 22, 1991 ACIP recommendations for routine hepatitis B vaccination for all infants were published in MMWR.
August 1991 The last case of indigenous polio in the Western Hemisphere occurred in a 5-year-old boy, Luis Fermin Tenorio, in Pichanaqui, Peru.
Jan 11, 1991 Recommendations of ACIP for routine Hib vaccination for infants beginning at 2 months of age were published in MMWR.
Dec 21, 1990 An enhanced-potency inactivated poliovirus vaccine (Ipol by Pasteur Méérieux Vaccins et Serums) was licensed.
April 13, 1990 ACIP recommendations for use of any of the three licensed Hib conjugate vaccines (ProHIBIT, HibTITER, and PedvaxHIB) for children as young as 15 months of age were published in MMWR.
Dec 20, 1989 Conjugated Haemophilus influenzae type b (Hib) vaccine (PedvaxHIB by Merck) was licensed.
Dec 15, 1989 A live, oral typhoid vaccine (Ty21a, Vivotif Berna by Swiss Serum Institute) was licensed.
Aug 28, 1989 Recombinant hepatitis B vaccine (Engerix-B by SmithKline Beecham) was licensed.
1989 Recommendations for routine 2nd doses of measles-containing vaccine were issued by both ACIP and the AAP. During the mid- to late-1980s, a high proportion of reported measles cases were in school-aged children (5-19 years) who had been appropriately vaccinated. These vaccine failures led to national recommendations for a second dose of measles-containing vaccine.
Dec 21, 1988 Conjugated Haemophilus influenzae type b vaccine (HibTITER by Wyeth-Lederle) was licensed.
1988 The Center for Biologics Evaluation and Research (CBER) was created within the FDA to regulate biological products, including blood, vaccines, tissue, allergenics, and biological therapeutics.
1988 The World Health Assembly (the ministers of health of all member states of the WHO) passed a resolution to eradicate polio by the year 2000.
1988 The National Vaccine Injury Compensation Program (NVICP) was established to provide compensation following a vaccine-related adverse event that resulted in injury or death. NVICP was intended to serve as an alternative to civil litigation. The law established a Vaccine Injury Table that provided a list of compensable vaccination events and, for each, an associated time period requirement.
Jan 22, 1988 ACIP recommendations to administer Hib conjugate vaccine to all children at 18 months of age were published in MMWR.
Dec 22, 1987 Protein-conjugated Haemophilus influenzae type b vaccine (PRP-D, ProHibit by Connaught) was licensed.
July 23, 1986 Recombinant hepatitis B vaccine (Recombivax HB by Merck) was licensed. Using recombinant DNA technology, Merck scientists developed a hepatitis B surface antigen subunit vaccine.
1986 Congress created the National Vaccine Program (NVP) to coordinate the vaccine research and development programs of AID, NIH, CDC, the Department of Defense, and FDA.
1986 The National Childhood Vaccine Injury Act of 1986 was enacted by Congress. The Department of Health and Human Services established the Vaccine Adverse Event Reporting System (VAERS), co-administered by FDA and CDC, to accept all reports of suspected adverse events, in all age groups, after the administration of any U.S.-licensed vaccine. The Act required healthcare providers and vaccine manufacturers to report to the Department of Health and Human Services specific adverse events following the administration of measles, mumps, rubella, polio, pertussis, diphtheria, and tetanus vaccine and any combinations thereof.
Apr 12, 1985 Haemophilus influenzae type b (Hib) polysaccharide vaccines (b-CAPSA 1 by Praxis Biologics, Hib-VAX by Connaught, and Hib-IMUNE by Lederle) were licensed. The vaccine was recommended routinely for children at 24 months of age and for children at 15 months of age enrolled in child care facilities. The vaccine was not consistently immunogenic in children <18 months of age.
Sept 1, 1984 The costs of hepatitis B vaccine and its administration became a covered benefit under Medicare Part B.
July 1983 Two enhanced pneumococcal polysaccharide vaccines were licensed (Pneumovax 23 by Merck on July 11 and Pnu-Imune 23 by Lederle on July 21). These vaccines included 23 purified capsular polysaccharide antigens of Streptococcus pneumoniae and replaced the 14-valent polysaccharide vaccine licensed in 1977.
1981 The first hepatitis B viral vaccines, developed by Merck and also by the Pasteur Institute, were licensed. Both had independently developed plasma-based hepatitis B viral vaccines.
Nov 23, 1981 Quadrivalent groups A, C, Y, and W-135 (Menomune A/C/Y/W-135 by Connaught) meningococcal vaccine was licensed. Because this and other polysaccharide meningococcal vaccines were found to induce a relatively poor immune response in children younger than two years and not able to elicit long-term immunologic memory, their use was limited to persons 2 years of age and older.
July 1, 1981 The costs of pneumococcal vaccine and its administration became a covered benefit under Medicare Part B.
May 8, 1980 The World Health Assembly certified the world free of naturally-occurring smallpox.
1980 Rabies human diploid-cell vaccine (Imovax Rabies by Mérieux and Wyvac by Wyeth) were licensed.
1979 The RA 27/3 (human diploid fibroblast) strain of rubella vaccine (Meruvax II by Merck) was licensed; all other strains were discontinued.
1979 The last cases of wild type 1 poliovirus occurred in the U.S. among unvaccinated Amish persons and members of other religious groups who did not accept vaccination. The source of the outbreak was determined to have been brought over to the U.S. from the Netherlands by members of an unvaccinated religious group.
Jan 3, 1978 Yellow fever vaccine (YF-Vax by Connaught) was licensed in the U.S.
Jan 3, 1978 Monovalent group A (Menomune-A by Connaught), group C (Menomune-C by Connaught) meningococcal vaccines, and a bivalent vaccine for both groups A and C (Menomune-A/C by Connaught) were licensed.
Nov 21, 1977 The first pneumococcal vaccine was licensed, containing 14 serotypes (of the 83 known serological groups) that comprised 80% of all bacteremic pneumococcal infections in the U.S.
Oct 26, 1977 The last case of naturally-acquired smallpox occurred in the Merca District of Somalia.
1977 Joseph A. Califano, Jr., Secretary of the Dept of Health, Education, and Welfare (later Health and Human Services) launched the National Childhood Immunization Initiative with a goal of achieving 90% vaccination levels among all children.
1976 The age for routine vaccination with MMR vaccine was changed from 12 months to 15 months.
Apr 2, 1974 The first monovalent (group C) meningococcal polysaccharide vaccine (Merck) was licensed.
1974 The Expanded Programme on Immunization was created within WHO, in response to poor immunization levels in developing countries (less than 5% of children in 1974). The following vaccines are used by the Expanded Programme on Immunization: BCG, polio, DTP, measles (often MMR), yellow fever (in endemic countries), and hepatitis B.
July 18, 1973 Measles and mumps virus vaccine, live (M-M-Vax by Merck) was licensed.
1972 The Division of Biologics Standards was transferred from NIH to FDA and renamed the Bureau of Biologics. It was responsible for the regulation of all biologics, including serums, vaccines, and blood products.
Apr 22, 1971 Combined measles, mumps, and rubella vaccine (MMR by Merck) as well as combined measles and rubella vaccine (M-R-Vax by Merck) were licensed; the vaccine was developed by Maurice Hilleman and colleagues at Merck.
1971 CDC recommended discontinuation of routine vaccination for smallpox in the U.S. following a greatly reduced risk of disease.
1969 Three rubella virus strains were licensed in the U.S.: HPV-77 strain grown in dog-kidney culture (Rubelogen by Parke-Davis); HPV-77 grown in duck-embryo culture (Meruvax by Merck); and Cendehill strain grown in rabbit-kidney culture (Cendevax by RIT-SKF, and Lirubel and Lirutrin by Dow).
1968 - 1969 The "Hong Kong" influenza pandemic, caused by an H3N2 influenza virus, resulted in roughly 34,000 deaths in the U.S.
1968 A second live, further attenuated measles virus vaccine (Attenuvax by Merck, based on the Moraten strain, derived from the Edmonston strain) was licensed.
1967 The Global Smallpox Eradication Program was launched by WHO. During the first year of the program, 44 countries, 31 of which had endemic smallpox, reported 217,218 cases.
Dec 28, 1967 Mumps virus vaccine live (MumpsVax by Merck) was licensed. The vaccine was developed by Maurice Hilleman who isolated a wild type virus from his daughter, Jeryl Lynn, who was recovering from mumps. It became known as the Jeryl Lynn strain of mumps virus.
1966 The World Health Assembly called for global smallpox eradication.
1966 CDC announced the first national measles eradication campaign. Within 2 years, measles incidence had decreased by more than 90% compared with prevaccine-era levels.
1966 The rubella virus was attenuated by Paul Parkman and Harry Meyer, Jr.
1965 Bifurcated needle for smallpox vaccine introduced
1965 Live, further attenuated measles virus vaccine (Lirugen by Pitman Moore-Dow based on the Schwarz strain, derived from the Edmonston strain) was licensed in the U.S. The recommended age for routine administration was changed from 9 to 12 months of age.
1964 A rubella epidemic swept the U.S. resulting in 12.5 million cases of rubella infection, an estimated 20,000 newborns with congenital rubella syndrome (CRS), and excess fetal and neonatal deaths in the thousands.
1964 The Immunization Practices Advisory Committee (ACIP) to the U.S. Public Health Service was formed to review the recommended childhood immunization schedule and note changes in manufacturers' vaccine formulations, revise recommendations for the use of licensed vaccines, and make recommendations for newly licensed vaccines.
June 25, 1963 Trivalent oral polio vaccine was licensed. The vaccine development began in 1957 by Albert Sabin to improve upon the killed Salk vaccine.
1963 The Federal Immunization Grant Program was established. The grants, authorized under section 317 of the Public Health Service Act, were made to states to provide funds to purchase vaccines and to support basic functions of an immunization program. The only vaccines available at the time were DTP, polio, and smallpox.
Mar 21, 1963 The first live virus measles vaccine (Rubeovax by Merck) was licensed. Other live virus measles vaccines were eventually licensed (M-Vac by Lederle, Pfizer-vax Measles-L by Pfizer, and generic vaccines by Lilly, Parke Davis, and Philips Roxane).
1963 Inactivated measles vaccine (Pfizer-vax Measles-K by Pfizer and a generic vaccine by Lilly) were licensed in the U.S. These vaccines were eventually withdrawn from the U.S. market in 1967.
1962 President John F. Kennedy signed the the Vaccination Assistance Act into law. It allowed the CDC to support mass immunization campaigns and to initiate maintenance programs.
Mar 27, 1962 Oral polio vaccine type 3 was licensed in the U.S., as well as the trivalent product.
1961 Oral polio vaccine types 1 and 2, developed by Dr. Albert Sabin and grown in monkey kidney cell culture, were licensed for use in the U.S.
1957 - 1958 The "Asian" influenza pandemic, caused by an H2N2 influenza virus, resulted in an estimated 70,000 deaths in the U.S. alone.
1955 The Polio Vaccination Assistance Act was enacted by Congress, the first federal involvement in immunization activities. It allowed Congress to appropriate funds to the Communicable Disease Center (later the Centers for Disease Control and Prevention) to help states and local communities acquire and administer vaccine.
1955 The Cutter polio vaccine incident began on April 25, 1955, when polio was reported in a vaccine recipient. One day later, five more cases were reported. All cases had received vaccine produced by Cutter Laboratories. Polio was reported in 94 vaccinees and in 166 close contacts of vaccinees. On April 27, the Laboratory of Biologics Control requested that Cutter Laboratories recall all vaccine and the company did so immediately. On May 7, the Surgeon General recommended that all polio vaccinations be suspended pending inspection of each manufacturing facility and thorough review of the procedures for testing vaccine safety. The investigation found that live polio virus had survived in two batches of vaccine produced by Cutter Laboratories. In 1955, as a result of the Cutter Incident, the Laboratory of Biologics Control was raised to division status within NIH, to strengthen and expand its biologics control function. Large-scale polio vaccinations resumed in the fall of 1955.
Apr 12, 1955 The first polio vaccine was licensed -- an inactivated poliovirus vaccine (IPV) pioneered by Dr. Jonas Salk.
1954 The Nobel Prize in Medicine was awarded to John Enders, Thomas Weller, and Fredrick Robbins for their discovery of the ability of poliomyelitis viruses to grow in tissue cultures.
1954 John Enders and Thomas Peebles isolated the measles virus in cell culture.
1953 Tetanus and diphtheria toxoids (adult formulation) was first licensed in the U.S., after the concentration of diphtheria toxoid was reduced.
May 22, 1953 Yellow fever vaccine (Merrell National Labs) was first licensed in the U.S.
July 16, 1952 Heat-phenol inactivated typhoid vaccine by Wyeth was licensed.
1952 The worst recorded polio epidemic in U.S. history occurred with 57,628 reported cases
1949 Diphtheria and tetanus toxoids and pertussis (DTP) was licensed.
1949 The last case of smallpox in the U.S. was reported; however, it took another two decades before the disease was eradicated globally.
1947 Combination diphtheria and tetanus toxoids for pediatric use was first licensed in the U.S.
1945 Inactivated influenza vaccine was first licensed in the U.S.
1945 K Habel and John Enders isolated the mumps virus.
1944 The Public Health Services Act of 1944 was enacted, consolidating all legislation affecting the functions of the Public Health Service.
1943 Penicillin first became mass-produced. This medical miracle, rediscovered by Alexander Fleming in 1928, was capable of attacking many types of disease-causing bacteria. It played a vital role in treating infected wounds during World War II.
1942 Influenza A/B vaccine was introduced to the Armed Forces Epidemiological Board. The influenza vaccine was licensed in 1945 and, following the war, was also used for civilians.
1942 Hepatitis A and B viruses were first differentiated.
1938 President Franklin D. Roosevelt, a victim of polio, founded the National Foundation for Infantile Paralysis, later known as the March of Dimes.
1937 An adsorbed form of tetanus toxoid was first licensed in the U.S.
1937 The Division of Biologics Control was formed within the National Institute of Health. Much later, in 1972, the Division was transferred to the FDA.
1935 A live yellow fever vaccine (17D) was first licensed. The development of the chorioallantoic membrane for culturing viruses had led to its development.
1930 The Hygienic Laboratory changed its name to the National Institute (singular) of Health and authorized the establishment of fellowships for biological and medical research.
1930 Cell culture was developed and shown to be able to grow virus, thus paving the way for the subsequent production of viral vaccines.
1928 The first iron lung was used to preserve breathing function in patients with acute polio.
1927 Bacille Calmette-Guerin (BCG) vaccine was first used in newborns, having been developed by Albert Calmette and Camille Guéérin in 1921. BCG (live-attenuated Mycobacterium bovis BCG) represented the only vaccine against tuberculosis. It has become the most widely administered of all vaccines in the WHO Expanded Programme for Immunization, but has been estimated to prevent only 5% of all potentially vaccine-preventable deaths due to tuberculosis.
1923 Diphtheria toxoid was licensed; prepared from the inactivated bacterial toxin that has lost its toxicity but retains its antitoxin producing properties. In 1924, Gaston Ramon discovered diphtheria toxoid. Along with the discovery of antitoxins, Ramon uncovered the role of adjuvant substances of immunity.
1918 The "Spanish flu" influenza pandemic was responsible for 25-50 million deaths worldwide and more than one-half million in the U.S. This virus was unusual because it spread so quickly, was so deadly, and exacted its worse toll among the young and healthy.
1915 Pertussis vaccine, a suspension of inactivated Bordetella pertussis cells, was licensed. Inactivated vaccines were prepared with a microorganism or virus that had been killed, usually with a chemical such as formaldehyde.
1914 Typhoid vaccine was first licensed in the U.S.
1914 Rabies vaccine was first licensed in the U.S.
1914 Tetanus toxoid was introduced following the development of an effective therapeutic serum against tetanus by Emil Von Behring and Shibasaburo Kitasato.
1908 The first county health departments in the U.S. were formed.
1906 The Pure Food and Drugs Act was formed, prohibiting interstate commerce in misbranded and adulterated foods, drinks, and drugs.
April 5, 1902 The Biologics Control Act was formed. It included the regulation of vaccine and antitoxin producers and required both licensing and inspections of manufacturers. The standards imposed by the 1902 Act resulted in bankruptcy for one-third of the companies manufacturing antitoxins and vaccines while benefiting the manufacturers already in compliance. Ten firms held licenses with the Laboratory of Hygiene following the 1902 Act.
1901 In St. Louis, 13 children died of tetanus-contaminated diphtheria antitoxin. In the autumn of 1901, nine children in Camden, New Jersey, died from tainted smallpox vaccine. Efforts to ensure the purity of biological treatments by government oversight followed with the Biologics Control Act of 1902.
1901 The first Nobel Prize for Physiology and Medicine was awarded to Emil von Behring for his work on the development of a diphtheria antitoxin (later known as antiserum).
1897 Plague vaccine was introduced, following the preparation of anti-plague horse serum at the Pasteur Institute by Alexandre Yersin. After demonstrating protection from disease in immunized animals, Yersin went to China with the vaccine to protect humans during a plague epidemic.
1896 Cholera and typhoid vaccines were first developed.
1893 City and state public health departments began mass production of diphtheria antitoxin, following its introduction in European laboratories.
1888 The Pasteur Institute was established as a rabies treatment center as well as an infectious diseases research and training institute.
1888 The diphtheria toxin was discovered by Emile Roux. Passive serum therapies were developed through the scientific contributions of many, including Emil Von Behring who developed the first effective therapeutic serum against diphtheria and Paul Ehrlich who developed enrichment and standardization protocol, which allowed for an exact determination of quality of the diphtheria antitoxins.
1887 Joseph Kinyoun established one of the country's first bacteriological laboratories in the Marine Health Service Hospital on Staten Island, NY. He was director of the Laboratory of Hygiene, which moved to Washington, D.C., in 1891. Kinyoun brought the latest techniques such as the procedure for preparing diphtheria antitoxin back from his visits to Europe.
1885 Louis Pasteur first used rabies vaccine in humans.
1884 The first live attenuated viral vaccine (rabies) was developed by Louis Pasteur, using dessicated brain tissue inactivated with formaldehyde.
1882 Robert Koch identified the tubercle bacillus as the cause of tuberculosis, subsequently called Koch's bacillus.
1881 Louis Pasteur and George Miller Sternberg almost simultaneously isolated and grew the pneumococcus organism.
1879 Louis Pasteur created the first live attenuated bacterial vaccine (chicken cholera)
1877 Louis Pasteur proposed The Germ Theory of Disease.
1798 Edward Jenner published his work on the development of a vaccination that would protect against smallpox. Two years earlier, in 1796, he had first speculated that protection from smallpox disease could be obtained through inoculation with a related virus, vaccinia or cowpox. He tested his theory by inoculating eight-year-old James Phipps with cowpox pustule liquid recovered from the hand of a milkmaid, Sarah Nelmes.
1798 The Marine Health Service was established in 1798 as the nation's first public health agency. It provided hospital care for merchant seamen and protected port cities against diseases such as smallpox, cholera, and yellow fever.
1721 Variolation was introduced to Great Britain.
1100s The variolation technique was developed, involving the inoculation of children and adults with dried scab material recovered from smallpox patients. Variations of variolation have been noted in Turkey, Africa, China, and Europe.
400 BC Hippocrates described mumps, diphtheria, epidemic jaundice, and other conditions
Related Resources
Interactive website from the College of Physicians of Philadelphia
History of Medicine
History of Medicine
NLM collects, preserves, makes available, and interprets for diverse audiences one of the world's richest collections of historical material related to human health and disease.
 
 
 
Immunization Action Coalition  •  2550 University Avenue West  •  Suite 415 North  •  Saint Paul, Minnesota  •  55114
tel 651-647-9009  •  fax 651-647-9131
 
This website is supported in part by a cooperative agreement from the National Center for Immunization and Respiratory Diseases (Grant No. 5U38IP000290) at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The website content is the sole responsibility of IAC and does not necessarily represent the official views of CDC.